May 27: The Week in Cancer News
A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.
Progress Against Cancer
A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible for intensive chemotherapy. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) in...
The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA) has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Azacitidine...
Esophageal cancer increases in the middle-aged and more from this week in cancer news.
New studies shine a light on the effects of a cancer diagnosis on mental health and suicide risk.
First child to receive CAR T-cell therapy celebrates 10 years cancer-free, and authorization denials delay treatment for patients with Medicare Advantage.
The 10-year survival beginning five years after diagnosis IS seen as about 10 percent lower than in age-matched general population, a gap that persists for many years, The study reports. People who were treated...
Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of certain adult...
As outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now